We thank Akiyama et al. (1) for providing evidence in support of our data demonstrating the importance of circulatingactivated (PD11CXCR51CD41) and tissue-resident (CXCR51CD41) T follicular helper (Tfh) cells in patients with IgG4related disease (IgG4-RD) and the role of Tfh cells supporting B cells to differentiate into plasmablasts to produce IgG4 antibodies (2) . They highlight important unresolved issues, specifically drivers for Tfh cell expansion in patients with IgG4-RD.
We wish to highlight the presence of a unique subset of circulating T peripheral helper (Tph PD1 hi CXCR5-CD41) cells in IgG4-RD, which may be able to recruit both Tfh cells and B cells to the sites of inflammation. Pathologically expanded Tph cells were recently identified in the circulation and nonlymphoid rheumatoid joints in patients with rheumatoid arthritis (3), and expressed factors including IL21, CXCL13, and inducible co-stimulatory molecule, enabling B cell help. Here, we show for the first time an increase in the percentage of circulating PD1 hi CXCR5-CD41 Tph cells in patients with active IgG4-related pancreatic and biliary disease compared with treated inactive disease (P 5 0.002) and healthy volunteers (P 5 0.04) (Figure 1, top panels) . The percentage of Tph cells correlates with the serum IgG4 level (P 5 0.02, r0.75) and IgG4-responder disease activity index (P 5 0.003, r 5 0.71) (Figure 1, bottom panels) . The absolute number of circulating Tph cells falls with corticosteroid treatment (P 5 0.03). We have demonstrated coexpression of CD41 T cells with CXCL13, a ligand of CXCR5, and inducible co-stimulatory molecule in affected tissues (pancreas, bile duct, and salivary gland) in IgG4-RD (2) .
Expanded Tph cells can express chemokine receptors that direct migration to inflamed sites, such as CCR2 and CCR5, and chemokines such as CXCL13, which may recruit CXCR5-expressing immune cells, including Tfh cells and B cells to initiate and maintain inflammation (4). As such, Tph cells may play a more pathogenic role than their Tfh counterparts in IgG4-RD immune pathogenesis. Key questions remain in the developmental relationship, origin, and differentiation of such cells in the context of IgG4-RD. Understanding the mechanisms underlying Tfh and Tph cell-mediated immunity and pathology may bring potential targets for novel therapies in this disease.
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